Transform Wealth LLC Grows Holdings in GSK plc (NYSE:GSK)

Transform Wealth LLC raised its holdings in GSK plc (NYSE:GSKGet Rating) by 2.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 149,383 shares of the pharmaceutical company’s stock after purchasing an additional 3,419 shares during the quarter. Transform Wealth LLC’s holdings in GSK were worth $6,553,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of GSK. Dodge & Cox grew its holdings in shares of GSK by 0.6% during the fourth quarter. Dodge & Cox now owns 88,519,444 shares of the pharmaceutical company’s stock worth $3,903,707,000 after buying an additional 501,530 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of GSK by 4.1% during the first quarter. Fisher Asset Management LLC now owns 18,967,209 shares of the pharmaceutical company’s stock worth $826,212,000 after buying an additional 750,042 shares during the last quarter. Black Creek Investment Management Inc. grew its holdings in shares of GSK by 0.4% during the fourth quarter. Black Creek Investment Management Inc. now owns 10,373,943 shares of the pharmaceutical company’s stock worth $457,491,000 after buying an additional 44,594 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of GSK by 32.5% during the first quarter. Arrowstreet Capital Limited Partnership now owns 9,621,370 shares of the pharmaceutical company’s stock worth $419,107,000 after buying an additional 2,362,274 shares during the last quarter. Finally, JTC Employer Solutions Trustee Ltd grew its holdings in shares of GSK by 50.4% during the first quarter. JTC Employer Solutions Trustee Ltd now owns 9,016,970 shares of the pharmaceutical company’s stock worth $392,735,000 after buying an additional 3,023,634 shares during the last quarter. 16.86% of the stock is currently owned by institutional investors and hedge funds.

GSK Price Performance

Shares of GSK stock traded down $0.85 during trading on Friday, hitting $29.16. 389,727 shares of the company were exchanged, compared to its average volume of 6,046,734. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 0.83. GSK plc has a fifty-two week low of $29.53 and a fifty-two week high of $46.97. The stock has a market capitalization of $59.30 billion, a price-to-earnings ratio of 9.64, a P/E/G ratio of 1.13 and a beta of 0.61. The firm has a 50 day moving average price of $35.90 and a 200 day moving average price of $40.93.

GSK (NYSE:GSKGet Rating) last issued its quarterly earnings data on Wednesday, July 27th. The pharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.76 by $0.11. GSK had a return on equity of 27.84% and a net margin of 12.91%. The firm had revenue of $8.71 billion during the quarter, compared to the consensus estimate of $9.35 billion. On average, equities analysts expect that GSK plc will post 3.23 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 6th. Investors of record on Friday, August 19th will be given a dividend of $0.383 per share. This is an increase from GSK’s previous quarterly dividend of $0.35. This represents a $1.53 annualized dividend and a dividend yield of 5.25%. The ex-dividend date of this dividend is Thursday, August 18th. GSK’s payout ratio is currently 50.66%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on GSK shares. Credit Suisse Group raised GSK from an “underperform” rating to a “neutral” rating in a report on Thursday, September 15th. AlphaValue lowered GSK to a “reduce” rating in a report on Tuesday, July 19th. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday. TheStreet lowered GSK from a “b” rating to a “c+” rating in a report on Monday, August 29th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on GSK from GBX 1,750 ($21.15) to GBX 1,500 ($18.12) in a report on Wednesday, September 7th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, GSK presently has a consensus rating of “Hold” and a consensus target price of $1,700.00.

About GSK

(Get Rating)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Read More

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKGet Rating).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.